REGENXBIO (NASDAQ:RGNX) Lowered to Sell Rating by StockNews.com

REGENXBIO (NASDAQ:RGNX) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a report released on Thursday.

Several other research firms have also commented on RGNX. Chardan Capital reissued a “buy” rating and set a $52.00 target price on shares of REGENXBIO in a research note on Wednesday, November 20th. Raymond James reissued an “outperform” rating and set a $18.00 target price on shares of REGENXBIO in a research note on Thursday, October 10th. Royal Bank of Canada reissued an “outperform” rating and set a $30.00 target price on shares of REGENXBIO in a research note on Tuesday. Morgan Stanley restated an “overweight” rating and issued a $22.00 price target on shares of REGENXBIO in a research report on Friday, November 15th. Finally, HC Wainwright restated a “buy” rating and issued a $36.00 price target on shares of REGENXBIO in a research report on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $34.82.

REGENXBIO Trading Up 1.3 %

RGNX stock traded up $0.10 on Thursday, hitting $7.95. 1,026,704 shares of the company’s stock traded hands, compared to its average volume of 1,321,670. REGENXBIO has a 1-year low of $6.56 and a 1-year high of $28.80. The stock has a market cap of $393.84 million, a price-to-earnings ratio of -1.58 and a beta of 1.28. The stock has a fifty day moving average of $8.52 and a 200-day moving average of $10.42.

Institutional Trading of REGENXBIO

Large investors have recently modified their holdings of the company. GAMMA Investing LLC boosted its holdings in shares of REGENXBIO by 273.1% during the 4th quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock worth $27,000 after buying an additional 2,510 shares during the period. FMR LLC boosted its holdings in shares of REGENXBIO by 166.8% during the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock worth $28,000 after buying an additional 1,656 shares during the period. nVerses Capital LLC boosted its holdings in shares of REGENXBIO by 183.3% during the 3rd quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock worth $36,000 after buying an additional 2,200 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in shares of REGENXBIO by 64.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock worth $100,000 after buying an additional 3,720 shares during the period. Finally, Erste Asset Management GmbH bought a new stake in shares of REGENXBIO during the 3rd quarter worth $140,000. 88.08% of the stock is owned by institutional investors.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.